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Abstract
Background: Recently, vitamin D3 (1alpha, 25-dihydroxyvitamin D) has shown its capability to take part in many
extraskeletal functions and its serum levels have been related to patient survival rate and malignancy of many types
of neoplasms, including ovarian cancers. Catalytic iron is a free circulating form of iron that is able to generate
reactive oxygen species and consequently to promote a number of cellular and tissutal dysfunctions including
tumorigenesis. In fertile women an important source of catalytic iron is derived from retrograde menstruation.
Epithelial secretory cells from fimbriae of fallopian tubes are greatly exposed to catalytic iron derived from
menstrual reflux and so represent the site of origin for most serous ovarian cancers.
The aim of this study was to assess whether vitamin D3 can play a role in counteracting catalytic iron-induced
oxidative stress in cells from fimbriae of fallopian tubes.
Methods: The cells, isolated from women undergoing isteroannessiectomy, were treated with catalytic iron
50-75-100 mM and vitamin D3 at a concentration ranging from 0.01 to 10 nM to study cell viability, radical oxygen
species production, p53, pan-Ras, Ki67 and c-Myc protein expressions through Western Blot, and
immunocytochemistry or immunofluorescence analysis.
Results: The pre-treatment with vitamin D3 1 nM showed its beneficial effects that consists in a significant decrease
in ROS production. In addition a novel finding is represented by the demonstration that pre-treatment with vitamin
D3 is also able to significantly counteract tumoral biomarkers activation, such as p53, pan-Ras, Ki67 and c-Myc, and
consequently the catalytic iron-induced cellular injury.
Conclusions: This study demonstrates for the first time that vitamin D3 plays an important role in preventing
catalytic iron-dependent oxidative stress in cultured fimbrial cells. These results support the hypothesis that vitamin
D3 could counteract carcinogenic changes induced by catalytic iron.
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Background
Recently, the role of 1alpha,25-dihydroxyvitamin D (VitD)
has greatly expanded from its classical function of modu-
lator of calcium metabolism and skeletal trophism into a
number of extraskeletal functions such as nitric oxide
production, antioxidant activity and endothelial prolifera-
tion and migration [1–3]. Along with its well-known
metabolic functions, VitD has recently shown immuno-
modulatory and anticancer properties as well [4–7]. As a
matter of fact, the importance of serum VitD level as a
biomarker for cancer risk was first determined by Garland
et al. in 1989 [8]. Moreover, Gorham et al. [9] confirmed
the relationship between VitD and cancer, showing that
an increase in the serum level of VitD to 34 ng/ml was
associated with a 50 % reduction in incidence rates of
colorectal cancer.
As regards ovarian cancer, it has been observed that
serum concentration of VitD was lower in cancer patients
than in the reference group (12.5 ± 7.75 ng/mL vs 22.4 ±
6.5 ng/mL) [10]. Moreover, low VitD serum concentration
is associated with lower overall survival rate. This fact
points out the importance of severe VitD deficiency as a
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possible cause of highly aggressive ovarian cancer [10]. In
addition, VitD treatment suppressed human epithelial ovar-
ian cancer cells migration and invasion in monolayer
scratch and transwell assays, as well as the ability to
colonize the omentum in an ex vivo experimental model.
These findings support a role for epithelial VitD receptor
(VDR) in interfering with epithelial ovarian cancer invasion
[11]. A recent systematic review states that there is no
consistent or strong evidence to support the claim made in
numerous review articles that VitD exposure reduces the
risk for ovarian cancer occurrence or mortality [12]. How-
ever, this declaration is in contrast with several human and
cell-based studies which show that VitD can induce growth
arrest and apoptosis either of tumor cells or of their non-
neoplastic progenitors [13, 14]. In addition, it has been
demonstrated that other gene targets related to DNA repair
and immunomodulation, as well as other cell targets such
as the stromal cells and cells of the immune system, may
be regulated by VitD, thus contributing to cancer preven-
tion [15]. The molecular mechanisms leading to cancer
prevention exerted by VitD have been extensively studied
in the last few years in order to identify a possible new
therapeutic strategy. A large number of studies have shown
that VitD has important anti-proliferative, anti-angiogenic
and pro-differentiative effects in a wide range of cancers.
These effects are mediated through perturbation of several
important signalling pathways mediated through genomic
and non-genomic mechanisms [16]. However these effects
have no uniform patterns of modulation by VitD across
different types of cancer cell lines. It has been hypothesized
that the heterogeneous action of VitD may depend on the
differentiation status of the cancer cells and VDR expres-
sion level, as well as genomic or post-translational modifi-
cations of co-activator proteins that are essential for the
assembly of the transcriptionally active VDR complex [17].
Catalytic iron (Fe3+) is a free circulating iron that is not
bound to transferrin or ferritin and is known to generate
reactive oxygen species that may have noxious effects on
cells and tissues. For example, a number of studies show
that high levels of Fe3+ may promote atherosclerosis [18],
endothelial dysfunction, arterial smooth muscle prolifera-
tion and ischemia/reperfusion injury [19, 20]. Blood-
deriving Fe3+ can accumulate into tissues and cells where
its ability to switch from its ferrous oxidation state into its
ferric one reversibly makes it very dangerous since free
iron can catalyze the formation of free radicals, which can
damage molecular components of the cell [21]. In a
chronic condition, high concentrations of heme and free
iron (Fe3+) derived from lysis of red blood cells by macro-
phages are able to exceed the capacity of ferritin to
sequester iron leading to oxidative injury. This mechanism
generates oxygen-free radicals leading to numerous
carcinogenic DNA mutations or loss, genetic instability,
overexpression of specific oncogenes, and downregulation
of tumor suppressor genes [22–24]. It has recently been
demonstrated that Fe3+, derived from menstrual reflux,
recently defined as “incessant menstruation” [25], is able
to induce an increase in fimbrial cell viability and prolifer-
ative capacity and to activate principal oncogenes (p53,
pan-Ras, Ki67 and c-Myc). So, it has been confirmed that
Fe3+ is capable to induce carcinogenic changes and repre-
sents the main non-genetic risk factor for ovarian cancer
[26]. For this reason, Fe3+ can be considered a putative
candidate as a transforming agent from normal human
fimbrial cells into cancer cells maintaining physiological
conditions of the menstrual cycle through oxidative stress
and consequent oncogenes activations.
This research was planned to study the role of VitD to
prevent oxidative injury induced by Fe3+ exposition in
primary fimbrial cells culture, because recent studies
have hypothesized that fimbrial fallopian tubes are the
site where most serous ovarian cancers develop [27, 28],
and the cells are subjected, to a constant carcinogenic
stimulus represented by Fe3+ [26], especially in presence
of low levels of serum VitD.
Methods
Samples
Thirty-six fresh fallopian tube-derived fimbriae were
obtained under written consent from women during ister-
oannessiectomy for ovarian cancer and benign pathology
without comorbidity at the II Department of Obstetrics
and Gynaecology of the Fondazione IRCCS Ca’ Granda,
Ospedale Maggiore Policlinico (Milan, Italy). All subjects
were in premenopause and had not received any type of
hormonal or drug therapy for at least 3 months. Approval
for this study was granted by the local Human Institu-
tional Investigation Committee.
Tissue collection
Thirty-six fresh fallopian tube-derived fimbriae tissues
were collected during isteroannessiectomy from 18
women and transported to laboratory in sterile falcon
containing saline solution (0.9 % w/v solution of sodium
chloride in distilled water, S.A.L.F, Cenate Sotto, Bergamo,
Italy) supplemented with 10 % penicillin/streptomycin
(Sigma, Milan, Italy). The tissue were obtained under
written consent at the II Department of Obstetrics and
Gynaecology of the Fondazione IRCCS Ca’ Granda, Ospe-
dale Maggiore Policlinico (Milan, Italy). Approval for this
study was granted by the local Human Institutional Inves-
tigation Committee. All 18 women were in premenopause
and had not received any type of hormonal or drug
therapy for at least 3 months before isteroannessiectomy
for ovarian cancer and benign pathology without
comorbidity.
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Primary cell preparation and culture
The isolation of epithelial secretory cells from fimbriae of
fallopian tubes (FSEC) has been described in detail in a
previous study [26]. Briefly, samples of fimbrial tissues
were washed, minced and incubated with Dulbecco’s
Modified Eagle Medium (DMEM, Sigma, Milan, Italy)
supplemented with 0.1 % type A collagenase, 1 % penicil-
lin/streptomycin and 2 mM L-Glutamine (Sigma, Milan,
Italy) for 2-3 h in incubator at 37 °C in agitation and cen-
trifuged at 600xg for 10 min at room temperature (RT).
The cell population of each patient have been kept separ-
ate and used for the experiments. One experiment was
performed on one population obtained from one patient.
Before the experiments, the purity of cell culture was
verified using a specific marker PAX8. The cells used had
passage 1-5 to have a complete cell phenotype.
To study cell viability (MTT test) and ROS production
1x104 cells were plated on 24 well-plates; to perform immu-
nohistochemistry and immunofluorescence studies 0.2x104
cells were placed in CultureSlide (BD, Bedford, MA, U.S.A.)
with 4 chambers; to analyze the intracellular pathways
through Western Blot analysis the cells were plated on
60 mm culture dish until confluence. Each experiment was
performed on 4 to 6 cell population of FSEC to obtained 4
or 6 technical replicates using 50, 75, 100 mM of Fe3+.
Experimental protocol
Each experiment was performed on 4 to 6 FSEC using
50, 75, 100 mM of Fe3+ [26] and 1nM VitD (based on
dose-response study) [2]. 1nM VitD was able to induce a
maximum effect on cell viability of FSEC. This concen-
tration was also verify in other work reported in litera-
ture [2]. This VitD concentration can ben considered
physiologically and clinically attainable because in
humans is comprised between 0.1 nM and 10 nM [29].
Experiments were performed using high doses of Fe3+
comparable to those observed in the content of endome-
triotic cysts [30]. In addition these concentrations were
also observed in a previous work on fimbrial cells to be
able to mimic carcinogenic changes [26]. FSEC were
incubated for two hours in DMEM without red-phenol
supplemented with 1 % penicillin/streptomycin, 2 mM L-
Glutamine and 0.5 % FBS before and during the treat-
ment. The stimulation with 1nM VitD was maintained
alone for 6 days and replicated as pretreatment for 6 days
before the stimulation with Fe3+ for other 6 days. The time
of stimulation of Fe3+ was the same used in a previous
work [26].
MTT test
MTT dye (Sigma-Aldrich) was used to determine cell
viability. After stimulation the cells were incubated with
1 % MTT dye for 2 h at 37 °C in incubator, as previously
described [2, 26].
Then, the medium was removed and the crystals were
dissolved in DMSO. Cell viability was measured through
a spectrometer (VICTORX3 Multilabel Plate Reader) at
570 nm with correction at 690 nm, and calculated by
comparing results to control cells (100 % viable).
ROS production
The rate of superoxide anion release was used to exam-
ine the effects of VitD against the oxidative stress in-
duced by Fe3+. The superoxide anion production was
measured as superoxide dismutase-inhibitable reduction
of cytochrome C, as previously described [2]. Briefly, in
all samples (stimulated and untreated), 100 μL of cyto-
chrome C was added and in another one, 100 μL of
superoxide dismutase was also added for 30 min in an
incubator (all substances from Sigma-Aldrich). The ab-
sorbance changes in the supernatants of the sample was
measured at 550 nm in a Wallac Victor model 1421
spectrometer (PerkinElmer). The O2 was expressed as
nanomoles per reduced cytochrome C per microgram of
protein, using an extinction coefficient of 21000 mL/cm,
after the interference absorbance subtraction [31].
Western Blot for VDR, PAX8, p53, c-Myc, Ki67 and pan-Ras
FSEC at confluence were washed three times with cold
PBS 1x supplemented with 2 mM sodium orthovana-
date, and then lysed in ice with Complete Tablet buffer
(Roche) supplemented with 2 mM sodium orthovana-
date and 50 μM MG132 (Sigma-Aldrich). Thirty-five μg
of proteins from each lysate were loaded on 15 or 5 %
SDS-PAGE gels and transferred to polyvinylidene fluor-
ide membranes (PVDF, GE Healthcare Europe GmbH,
Milan, Italy). They were incubated overnight at 4 °C with
specific primary antibody: anti-PAX8 (1:500, Abnova,
DBA ITALIA S.r.l., Milan, Italy), anti-VDR (1:200, Santa-
Cruz), anti-p53 (1:500, Santa-Cruz), anti-cMyc (1:200,
Millipore S.p.A., Milan, Italy), anti-Ki67 (1:500, Santa-
Cruz), and anti-pan-Ras (1:500, Santa-Cruz). Protein ex-
pression was normalized and verified through ß-actin
detection (1:5000; Sigma, Milan, Italy).
VDR, PAX8, c-Myc, Ki67 and pan-Ras immunocytochem-
istry in cellular preparation
FSEC cultured in chamber slide as described above were
washed three times with cold PBS 1x supplemented with
2 mM sodium orthovanadate, and fixed using a cold fixa-
tive solution (3.7 % formaldehyde, 3 % sucrose in PBS 1X)
for 20 min at RT. Then the cells were washed twice with
cold PBS 1X, permeabilized with cold PBS 1X with cold
0.5 % Triton X-100 on ice at 4 °C for 20 min and then
washed with PBS 1X. Then the chamber slides were incu-
bated with 3 % hydrogen peroxide in PBS 1X for 8 min to
block endogenous peroxidase activity and then maintained
in a blocking solution composed of PBS 1X with 3 %
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albumin from bovine serum (BSA, Sigma, Milan, Italy) for
1 h at RT. The slides were subsequently incubated over-
night at 4 °C with specific primary antibody: 1:150 PAX8,
1:50 VDR, 1:50 c-Myc, 1:50 Ki67 and 1:50 pan-Ras. All
these antibodies were diluted in PBS 1X in a humidified
chamber, and then incubated for 20 min with diluted bio-
tinylated secondary antibody solution (Dako Italia, Milan,
Italy) and then for 20 min with VECTASTAIN® ABC
Reagent (Dako Italia, Milan, Italy). Finally the sections
were washed, incubated with peroxidase substrate solution
until desired stain intensity developed (Peroxidase/DAB,
Dako Italia, Milan, Italy), rinsed in tap water, counter-
stained with Mayer’s hematoxylin and mounted with Bio
Mount (Bio-Optika, Milan, Italy). The number of positive
cells was calculated as described elsewhere [32]: briefly, 12
different areas (1 mm2) randomly selected from each
section were taken, and the number of signals was deter-
mined using ImagePro 3 software (NIH, Bethesda, US).
The results were expressed as a means ± SD (%).
p53 immunofluorescence in cellular preparation
After the stimulations the cells were fixed using cold buf-
fer PAF for 20 min, washed three times with cold PBS 1X
and then permeabilized with cold PBS 1X with 0.5 % Tri-
ton X-100 for 20 min at 4 °C. After this time slides were
incubated in blocking solution (1 % BSA and 5 % FBS in
PBS 1X) for 30 min at RT and treated with p53 specific
antibody (1:50, Santa-Cruz) in PBS 1X overnight at 4 °C.
The slides were then incubated with fitch-secondary anti-
bodies (1:200, Sigma-Aldrich) in PBS 1X for 1 h in the
dark, counterstained with DAPI (1 μg/ml; Sigma-Aldrich)
diluted in PBS 1X for 5 min in the dark at RT and finally
mounted in Vectashield (D.B.A. Italia). The number of
positive cells was calculated as described by Lee et al. [32]:
briefly, 12 different areas (1 mm2) randomly selected from
each section were taken, and the number of signals was
determined using ImagePro 3 software (NIH, Bethesda,
US). The results were expressed as means ± SD (%).
Statistical analysis
Results are expressed as means ± SD of at least 4 inde-
pendent experiments for each experimental protocol.
One-way ANOVA followed by Bonferroni post hoc test
was used for statistical analysis. The percentage values
were compared through Mann-Whitney U test. P-value
<0.05 was considered statistically significant.
Results
Dose-response study, cell viability and reactive oxygen
species (ROS) production
The cell viability induced by stimulation of FSEC with
VitD (from 0.01 to 10 nM, dissolved in ethanol), was
measured in a dose-response study after 6 days by MTT
test. As illustrated in Fig. 1a, the effect of VitD on cell
viability by a dose-response study was examined and it
was concentration-dependent with a maximum effect at
1 nM concentration after 6 days of stimulation (48.60 ±
2.93 %, P < 0.05). This concentration was used for all
successive experiments. The effect of the solvent of VitD
on FSEC was also tested. In addition the influence of
VitD on the effects exerted by Fe3+ on cell viability of
FSEC was studied. The cells were divided into two
groups: one treated with different concentrations of Fe3+
for 6 days and one pre-treated with 1 nM VitD for 6 days
and then stimulated with the same concentrations of Fe3
+ (50-75-100 mM). Pre-treatment was also performed
using ethanol alone (solvent of VitD). As reported in
Fig. 1b, the pre-treatment with VitD was able to counter-
act the increase on cell viability induced by Fe3+ in a
dose-dependent manner, and the maximum effects were
observed in presence of 100 mM Fe3+ (1.033 ± 0.04 %, P
< 0.05) in respect with Fe3+ alone.
The same conditions described before were repro-
duced to analyze the ROS production in FSEC. In cells
treated with Fe3+ we observed a significant increase in
ROS production in a dose-dependent manner compared
with control (Fig. 1c, P < 0.05), and the maximum effects
was obtained by 100 mM Fe3+ (114.6 ± 1.84 Cytochrome
C reduced per μg of protein). In FSEC treated with VitD
alone a significant reduction in ROS production com-
pared to control was observed (13.08 ± 1.53 Cytochrome
C reduced per μg of protein). The pre-treatment with
VitD was able to counteract the ROS production in-
duced by Fe3+ and this effect was more evident in pres-
ence of 75 mM (21.09 ± 2.46 Cytochrome C reduced per
μg of protein) and 100 mM Fe3+ (50.27 ± 6.59 Cyto-
chrome C reduced per μg of protein) compared with Fe3
+ alone (47.40 ± 1.86 and 114.6 ± 1.84 Cytochrome C re-
duced per μg of protein, respectively). These data con-
firmed previous findings on MTT test, and demonstrate
the ability of VitD to prevent the effects of oxidative
stress only if it used before the oxidative damage.
PAX8 and VDR receptor analysis
FSEC were tested for specific fimbrial marker PAX8 in
immunocytochemistry and Western blot analysis (Figs. 2a
and 3a) to verify the efficacy of cell isolation and the
preservation during the stimulation with Fe3+ and VitD
(as showed nuclear/perinuclear staining by immunocyto-
chemistry). The presence of VDR receptor in FSEC were
determined to demonstrate the efficacy of VitD in these
cells. The presence of VDR receptor was evident in im-
munocytochemistry (Fig. 2b), in which 98 ± 2 % of FSEC
had cytoplasmic-nuclear staining positive and this in-
crease compared to control was also observed by West-
ern blot analysis (Fig. 3b). Indeed the expression was
augmented compared to control (about 50 %, P < 0.05)
in presence of VitD alone or in samples pre-treated with
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VitD. These data demonstrate that VitD is able to
explain its effects through VDR receptor signaling
through genomic action.
p53, pan-Ras, Ki67, and c-Myc Analysis in FSEC
p53, pan-Ras, Ki67, and c-Myc expressions were investi-
gated in FSEC treated with Fe3+ alone and after pre-
treatment with VitD by Western blotting (Fig. 4) and
immunofluorescence or immunocytochemistry (Fig. 5).
The effects of VitD alone on these pathways were also
tested in the same protocols (Figs. 4 and 5). In presence of
Fe3+ p53, pan-Ras, Ki67, and c-Myc activations were ob-
served in a dose-dependent manner, and the maximum ef-
fects were observed with Fe3+ 100 mM after 6 days of
treatment (2.88 ± 1.06; 1.74 ± 1.03; 10.13 ± 1.23;1.28 ± 1.01
ratio of activation, respectively) compared to control
values by Western blotting (Fig. 4). Similar data were also
observed in immunofluorescence (p53) and immunocyto-
chemistry experiments (pan-Ras, Ki67, c-Myc) performed
in FSECs (Fig. 5). The pre-treatment with VitD for 6 days
was able to counteract p53, pan-Ras, Ki67, and c-Myc
activations (Figs. 4 and 5): these effects were clearer in
samples treated with Fe3+ 100 mM (64 %; 42 %; 87 %;
22 % of reduction, respectively by Western Blot analysis).
In addition the effects of VitD alone were also tested and
didn’t reveal a significant activation of tumoral markers
(P < 0.05) compared to control values.
Discussion
It has been demonstrated that the site of origin of most
high grade serous ovarian cancers is the fallopian tube
secretory epithelial cells [33]. Recent studies hypothe-
sized the role of retrograde menstruation-derived Fe3+ in
increasing risk of ovarian cancer [25], due to a severe
oxidative injury induced by iron [26, 34, 35]. Fimbria in
the pouch of Douglas is exposed to generated from
hemolysis of erythrocytes by pelvic macrophage during
retrograde menstruation, a common physiologic event in
all menstruating women [25]. In addition, Seidman [35]
Fig. 1 Effects of VitD on cell viability and ROS production. a,
dose-response study of VitD (0.01-100 nM) on cell viability of FSEC.
The results are expressed as means ± SD (%) normalized to control
values of 5 technical replicates. * P < 0.05 vs control. b, MTT test
performed in FSEC treated with different doses of Fe3+ (50-100 mM)
alone for 6 days or pretreated with 1nM VitD for 6 days. The results
are expressed as means ± SD (%) normalized to control values of
6 technical replicates. ET-OH = ethanol * P < 0.05 vs control; arrows
indicate P < 0.05 between Fe3+ alone and VitD + Fe3+ c, ROS
production (expressed as Cytochrome C reduced per μg of protein)
in FSEC treated with different doses of Fe3+ (50-100 mM) alone for
6 days or pretreated with 1nM VitD for 6 days. The results are
expressed as means ± SD of 5 technical replicates. ET-OH = ethanol.
* P < 0.05 vs control; ** P < 0.05 vs VitD; # P < 0.05 vs ET-OH; arrows
indicate P < 0.05 between Fe3+ alone and VitD + Fe3+
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Fig. 2 PAX-8 and VDR receptor analysis by immunocytochemistry. On the left the score of positive cells, counted in 12 different areas, and on
the right the representative pictures, obtained through microscopy at original magnification of X40, are reported. A, PAX-8 staining: the ratio is
reported as mean (SD) (%) of positive cells of 4 technical replicates. The scale reported in the first column on the right is to be considered valid
for the same antibody. B, score of positive cells for VDR receptor is reported as mean (SD) (%) of 4 technical replicates. * P < 0.05 vs control;
** P < 0.05 vs VitD. The scale reported in the first column is to be considered valid for the same antibody
Fig. 3 PAX-8 (a) and VDR (b) studies by Western Blot and densitometric analysis. Protein extracts has been analyzed by immunoblotting with
specific antibodies against the indicated proteins. Data are expressed as means of 4 technical replicates performed on FSEC. * P < 0.05 vs control;
** P < 0.05 vs VitD; arrows indicate P < 0.05 between Fe3+ alone and VitD + Fe3+
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Fig. 4 Western Blot and densitometric analysis of p53 (a), Pan-Ras (b), Ki67 (c) and c-Myc (d). Protein extracts were analyzed by immunoblotting
with specific antibodies against the indicated proteins. Data are expressed as means of 5 technical replicates performed on FSEC. * P < 0.05 vs
control; ** P < 0.05 vs VitD; arrows indicate P < 0.05 between Fe3+ alone and VitD + Fe3+
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showed the presence of mucosal iron in fallopian tubes
in advanced-grade pelvic serous carcinoma [36]. In a
previous work, Lattuada et al. [26] demonstrates in
FSEC the involvement of Fe3+ in carcinogenic changes
using Fe3+ at highly doses [22, 30]. This study demon-
strates for the first time that VitD plays an important
role in preventing Fe3+-dependent oxidative stress in
cultured fimbrial cells. Experiments were performed
using 1 nM VitD. Experiments using Fe3+ have been
preceded by a dose-response study showing that the best
effect on cell viability was obtained with 1 nM VitD and
the optimum range is between 0.1 and 10 nM. This is the
concentration range considered physiologically and clinic-
ally attainable in humans [29]. The great decrease observed
in cell viability after 100 nM VitD administration depends
primarily on saturation of the intracellular pathways
controlling viability. This effect is still higher than the con-
trol. The beneficial effect of VitD consists in a significant
decrease of oxidative state showed by a significant decrease
in ROS production in culture supernatants. However the
ability of VitD to block oxidative injury has been tested only
when this substance has been administered before Fe3+.
These findings support previous studies in which the
relationship between low VitD serum concentration and
overall survival rate of patients with ovarian cancer has
been demonstrated [10]. Moreover, the important role of
severe VitD deficiency in more aggressive course of ovar-
ian cancer has been described [6, 35–37]. The effects of
VitD have been observed in FSEC with a high grade of
culture purity (PAX-8 positivity) along with the
Fig. 5 p53 (a), Pan-Ras (b), Ki67 (c) and c-Myc (d) analysis by immunofluorescence (panel A) or immunocytochemistry (panel B-D). On the left the score
of positive cells, counted in 12 different areas, and on the right the representative pictures, obtained through microscopy at original magnification of
X40, are reported. The ratio is reported as mean (SD) (%) of positive cells of 5 technical replicates. The scale reported in the first column on the right is
to be considered valid for the same antibody. * P < 0.05 vs control; ** P < 0.05 vs VitD; arrows indicate P < 0.05 between Fe3+ alone and VitD + Fe3+
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activation of VDR. For this reason mechanisms under-
lying protective effects of VitD may be hypothesized to
have genomic origin.
p53, pan-Ras, Ki67 and c-Myc has been analyzed in
FSEC treated with VitD alone or before Fe3+, to clarify the
protective mechanism activated by VitD. A novel finding
is represented by the demonstration that pre-treatment
with VitD is able to significantly counteract tumoral
biomarkers activation, suggesting the inhibition of epithe-
lial cell transformation. Thus our findings indicate that
VitD prevented the activation of p53, pan-Ras, Ki67, and
c-Myc. On the contrary, Fe3+ alone was able to mimic in
FSEC, through these tumoral biomarkers, the carcino-
genic changes typical of serous ovarian cancer.
As concerns Fe3+ concentration adopted in this study, it
must be considered that cellular iron homeostasis is regu-
lated by cytosolic regulatory proteins that bound structural
elements (iron-response elements) present in the messen-
ger RNA of some major proteins such as transferrin recep-
tor and ferritin. For this reason it is difficult to quantify the
plasmatic concentration of free Fe3+. However, in this study,
it has been chosen to use a Fe3+ concentration similar to
that found in endometriotic cysts [30].
The importance of these data is remarkable since the Fe3
+ concentration used in these experiments may induce car-
cinogenic changes as reported by many studies [26, 38, 39].
Conclusions
The results described herein highlight that VitD exerts
protective effects against Fe3+-related oxidative stress in
cultured FSEC. The discussed results could be relevant
in the light of the use of serum VitD levels assessment
to promote VitD supplementation or to adjust thera-
peutic strategies in ovarian cancer patients.
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